See more : Chofu Seisakusho Co., Ltd. (5946.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bactiguard Holding AB (publ) (BACTI-B.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bactiguard Holding AB (publ), a leading company in the Medical – Devices industry within the Healthcare sector.
- Sagami Holdings Corporation (9900.T) Income Statement Analysis – Financial Results
- Tarkett S.A. (TKTT.PA) Income Statement Analysis – Financial Results
- Eniro Group AB (publ) (ENRO-PREF-B.ST) Income Statement Analysis – Financial Results
- Anvia Holdings Corporation (ANVV) Income Statement Analysis – Financial Results
- JiShi Media Co., Ltd. (601929.SS) Income Statement Analysis – Financial Results
Bactiguard Holding AB (publ) (BACTI-B.ST)
About Bactiguard Holding AB (publ)
Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics. The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention. The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 203.99M | 223.56M | 169.49M | 172.32M | 184.99M | 150.10M | 147.46M | 118.74M | 131.42M | 109.05M | 126.73M | 129.01M | 4.38M | 117.52M | 127.01M |
Cost of Revenue | 64.01M | 43.42M | 38.68M | 35.19M | 32.06M | 25.72M | 20.26M | 15.80M | 7.90M | 6.10M | 10.29M | 2.77M | 316.00K | 4.56M | 2.97M |
Gross Profit | 139.98M | 180.14M | 130.80M | 137.12M | 152.93M | 124.38M | 127.20M | 102.94M | 123.52M | 102.95M | 116.44M | 126.24M | 4.07M | 112.95M | 124.04M |
Gross Profit Ratio | 68.62% | 80.58% | 77.18% | 79.58% | 82.67% | 82.87% | 86.26% | 86.70% | 93.99% | 94.40% | 91.88% | 97.86% | 92.79% | 96.12% | 97.66% |
Research & Development | 4.97M | 32.28M | 30.40M | 28.33M | 26.48M | 25.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 83.23M | 56.10M | 49.33M | 43.51M | 56.43M | 42.33M | 46.70M | 56.29M | 54.19M | 41.26M | 45.04M | 0.00 | 27.39M | 13.08M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 0.00 | 83.23M | 56.10M | 49.33M | 43.51M | 56.43M | 42.33M | 46.70M | 56.29M | 54.19M | 41.26M | 45.04M | 0.00 | 27.39M | 13.08M |
Other Expenses | 266.95M | 151.14M | 125.89M | 107.23M | 94.16M | 79.99M | 87.66M | 78.64M | 83.54M | 76.66M | 66.03M | 73.81M | 18.16M | 122.85M | 107.06M |
Operating Expenses | 271.91M | 234.37M | 181.99M | 156.56M | 137.67M | 136.42M | 129.99M | 125.34M | 139.83M | 130.85M | 107.30M | 118.85M | 18.16M | 150.24M | 120.15M |
Cost & Expenses | 335.92M | 277.79M | 220.68M | 191.75M | 169.73M | 162.14M | 150.25M | 141.13M | 147.73M | 136.95M | 117.59M | 121.62M | 18.47M | 154.80M | 123.11M |
Interest Income | 5.24M | 1.17M | 4.00K | 25.00K | 91.00K | 38.00K | 0.00 | 2.00K | 3.00K | 130.00K | 5.00K | 438.00K | -11.60M | 0.00 | 0.00 |
Interest Expense | 13.53M | 8.70M | 8.37M | 8.81M | 8.51M | 5.93M | 5.06M | 15.23M | 19.15M | 36.72M | 50.21M | 49.57M | 3.43M | 0.00 | 0.00 |
Depreciation & Amortization | 43.64M | 49.24M | 47.00M | 41.18M | 39.46M | 32.25M | 35.02M | 33.38M | 32.85M | 30.13M | 28.84M | 27.85M | 8.62M | 96.55M | 92.59M |
EBITDA | -89.98M | -543.00K | -5.94M | 9.22M | 59.12M | 19.54M | 33.16M | 17.28M | 21.10M | -18.05M | 73.78M | 27.61M | -5.47M | 59.26M | 96.48M |
EBITDA Ratio | -44.11% | -0.85% | -4.45% | 13.02% | 32.97% | 12.94% | 22.49% | 14.55% | 16.00% | -30.54% | 57.82% | 20.80% | -124.81% | 50.43% | 75.97% |
Operating Income | -131.93M | -54.23M | -51.19M | -21.85M | 19.51M | -12.04M | -582.00K | -18.27M | -12.67M | -19.79M | 11.16M | 8.29M | -14.09M | -37.29M | 3.90M |
Operating Income Ratio | -64.68% | -24.26% | -30.20% | -12.68% | 10.55% | -8.02% | -0.39% | -15.39% | -9.64% | -18.15% | 8.81% | 6.43% | -321.52% | -31.73% | 3.07% |
Total Other Income/Expenses | -15.22M | -4.19M | -9.06M | -20.08M | -9.16M | -8.66M | -7.71M | -13.07M | -18.30M | -64.66M | -16.93M | -58.88M | -5.93M | 12.54M | 3.77M |
Income Before Tax | -147.15M | -59.86M | -63.25M | -41.93M | 10.35M | -20.70M | -8.29M | -31.33M | -30.97M | -100.15M | -5.77M | -50.59M | -15.31M | -24.75M | 7.67M |
Income Before Tax Ratio | -72.14% | -26.77% | -37.32% | -24.34% | 5.60% | -13.79% | -5.62% | -26.39% | -23.57% | -91.84% | -4.55% | -39.21% | -349.27% | -21.06% | 6.04% |
Income Tax Expense | -8.77M | -6.98M | -4.48M | -3.54M | -5.90M | -5.76M | -5.04M | -4.48M | -4.47M | -5.10M | -2.37M | -12.23M | 1.22M | -12.54M | -3.77M |
Net Income | -138.38M | -52.88M | -58.77M | -38.39M | 16.26M | -14.93M | -3.25M | -26.85M | -26.50M | -95.04M | -3.41M | -38.36M | -15.31M | -24.75M | 7.67M |
Net Income Ratio | -67.84% | -23.65% | -34.68% | -22.28% | 8.79% | -9.95% | -2.20% | -22.61% | -20.17% | -87.16% | -2.69% | -29.73% | -349.27% | -21.06% | 6.04% |
EPS | -3.95 | -1.51 | -1.68 | -1.14 | 0.49 | -0.45 | -0.10 | -0.81 | -0.80 | -3.80 | -340.70 | -3.84K | -1.53K | -2.48K | 766.90 |
EPS Diluted | -3.95 | -1.51 | -1.68 | -1.14 | 0.49 | -0.45 | -0.10 | -0.81 | -0.80 | -3.80 | -340.70 | -3.84K | -1.53K | -2.48K | 766.90 |
Weighted Avg Shares Out | 35.04M | 35.04M | 35.04M | 33.54M | 33.30M | 33.30M | 33.30M | 33.30M | 33.30M | 25.01M | 10.00K | 10.00K | 10.00K | 10.00K | 10.00K |
Weighted Avg Shares Out (Dil) | 35.04M | 35.04M | 35.04M | 33.54M | 33.30M | 33.30M | 33.30M | 33.30M | 33.30M | 25.01M | 10.00K | 10.00K | 10.00K | 10.00K | 10.00K |
Source: https://incomestatements.info
Category: Stock Reports